Top news from MedWatch this week

Monday
Series of setbacks have not caused Orphazyme CEO to consider departing
Novo Nordisk CEO's pay sets itself apart on especially one point
Orphazyme not seeking fresh capital despite reduced cash position
Tuesday
Roche's digital health venture boosted by pandemic
Leo Pharma's new drug for atopic dermatitis receives EU approval
Financial analyst: Novo Nordisk's obesity treatment could triple market
Wednesday
US dermatology top boss moves to Danish biotech firm
Janssen gets expanded authorization for Genmab's Darzalex in EU
Leo Pharma receives UK approval for Adtralza
Thursday
Zealand Pharma sends blood sugar drug to US market
Oticon Medical gets FDA approval for cochlear implant
Novo Holdings sees golden opportunity in dialysis company, contributes to USD 245m investment
Friday
CHMP recommends eight new drugs for approval – one cancer drug rejected
Oticon president satisfied with FDA approval: "A huge milestone"
Pharmacosmos launches cell therapy market offensive